Truist Financial Remains a Buy on Scholar Rock Holding (SRRK)
Strategic Positioning and Market Potential: Scholar Rock Holding's Buy Rating Amidst SMA and Obesity Treatment Opportunities
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $57
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
TD Cowen Maintains Scholar Rock(SRRK.US) With Buy Rating
Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Initiates Scholar Rock(SRRK.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
Promising Market Dynamics and Growth Potential for Scholar Rock's Apitegromab Boost Buy Rating
Scholar Rock Holding Is Maintained at Buy by HC Wainwright & Co.
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
Scholar Rock Holding Is Maintained at Buy by Truist Securities
Scholar Rock Holding Analyst Ratings
Scholar Rock Holding: Strategic Positioning and Pipeline Progress Justify Buy Rating Amid Reduced Competition
TD Cowen Maintains Scholar Rock(SRRK.US) With Buy Rating